Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albendazole + secnidazole is a combination of two small-molecule antiparasitic and antimicrobial agents. Albendazole is a benzimidazole anthelmintic that inhibits microtubule polymerization by binding to β-tubulin in susceptible parasites, leading to impaired glucose uptake and depletion of energy stores, ultimately causing parasite death[6][8][10]. Secnidazole is a nitroimidazole antimicrobial that exerts its effect by reduction of its nitro group within anaerobic organisms, generating reactive intermediates that damage DNA and other critical biomolecules, resulting in cell death[4][9]. This combination has been used as an alternative therapy for refractory giardiasis (Giardia lamblia infection), particularly in pediatric patients who have failed conventional treatments. The regimen has demonstrated efficacy with good tolerability in small clinical series[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albendazole + secnidazole.